Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Benesch

Showing results (111-120 of 151) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 14, 2011
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastomaNicolas U Gerber, Katja von Hoff, André O von Bueren, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2009
Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91Katja von Hoff, Bernward Hinkes, Nicolas U Gerber, et al.
Acta Neuropathologica|April 12, 2021
Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtypeCatena Kresbach, Mario M Dorostkar, Abigail K Suwala, et al.
Cancer Reports (Hoboken, N.J.)|March 23, 2021
Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from AustriaAnna Füreder, Gabriele Kropshofer, Martin Benesch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91Stefan Rutkowski, André von Bueren, Katja von Hoff, et al.
Cancers|April 3, 2021
A Profound Basic Characterization of eIFs in Gliomas: Identifying eIF3I and 4H as Potential Novel Target Candidates in Glioma TherapyStefanie Krassnig, Christina Wohlrab, Nicole Golob-Schwarzl, et al.
Neuro-Oncology|April 5, 2024
Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatmentDenise Obrecht-Sturm, Lena Schömig, Martin Mynarek, et al.
Journal of Neuro-Oncology|December 12, 2012
Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groupsMartin Benesch, André O von Bueren, Tobias Dantonello, et al.
Journal of Neurosurgery. Pediatrics|June 19, 2026
Incomplete tumor resection, central neuroradiological review, and second surgery in pediatric patients with intracranial ependymoma treated in the E-HIT2000 trialKara L Krajewski, Gertrud Kammler, Denise Obrecht-Sturm, et al.
Cancers|February 5, 2021
Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94Stefan Fiedler, Inge M Ambros, Evgenia Glogova, et al.
Pageof 16

Showing results (111-120 of 151) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|December 14, 2011
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastomaNicolas U Gerber, Katja von Hoff, André O von Bueren, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2009
Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91Katja von Hoff, Bernward Hinkes, Nicolas U Gerber, et al.
Acta Neuropathologica|April 12, 2021
Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtypeCatena Kresbach, Mario M Dorostkar, Abigail K Suwala, et al.
Cancer Reports (Hoboken, N.J.)|March 23, 2021
Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from AustriaAnna Füreder, Gabriele Kropshofer, Martin Benesch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91Stefan Rutkowski, André von Bueren, Katja von Hoff, et al.
Cancers|April 3, 2021
A Profound Basic Characterization of eIFs in Gliomas: Identifying eIF3I and 4H as Potential Novel Target Candidates in Glioma TherapyStefanie Krassnig, Christina Wohlrab, Nicole Golob-Schwarzl, et al.
Neuro-Oncology|April 5, 2024
Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatmentDenise Obrecht-Sturm, Lena Schömig, Martin Mynarek, et al.
Journal of Neuro-Oncology|December 12, 2012
Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groupsMartin Benesch, André O von Bueren, Tobias Dantonello, et al.
Journal of Neurosurgery. Pediatrics|June 19, 2026
Incomplete tumor resection, central neuroradiological review, and second surgery in pediatric patients with intracranial ependymoma treated in the E-HIT2000 trialKara L Krajewski, Gertrud Kammler, Denise Obrecht-Sturm, et al.
Cancers|February 5, 2021
Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94Stefan Fiedler, Inge M Ambros, Evgenia Glogova, et al.
Pageof 16